Low-dose cytosine arabinoside; disease free survival and overall survival in the elderly patients with acute myeloid leukemia

ABSTRACT

The median age of the patients with acute myeloid leukemia [AML] is 65 years. Studies have revealed that the prognosis of the elderly patients [over 60 years] is not satisfying. The aim of this study was to evaluate the survival of AML patients being treated with Low-dose Cytosine arabinoside. In this cross-sectional study, 20 AML patients treated with Low-dose Cytosine arabinoside. Disease free survival and overall five-year survival ratios were identified. In this study there were 11 males [55%] and nine female [45%] with a mean age of 63.3 +/- 18.4 years. The median of disease free survival was 12.4 months and five-year survival was 1.7 years. Apparently disease-free survival and overall five-year survival in the AML patients being treated with Low-dose Cytosine arabinoside are similar to that of cases being treated with intense chemotherapy regimens